
Evidence in focus | Publication summary

TEG® 6s heparin neutralization cartridge for hemostatic assessment of patients undergoing cardiovascular surgery

Adelmann D, et al. Anesthesiology. **(2025)***

Key takeaway

This study validates the new TEG® 6s assays (RapidTEG™ with heparinase and Functional Fibrinogen with heparinase) in patients receiving unfractionated heparin during cardiovascular surgery or procedures.




Overview

Systemic heparinisation during cardiac surgery and interventional procedures can significantly affect thromboelastography measurements. The addition of heparinase to RapidTEG and Functional Fibrinogen assays in the recently cleared TEG® 6s Global Haemostasis - HN cartridge overcomes this limitation. This study provides clinical validation of the HN cartridge, in cardiovascular surgery/procedures using unfractionated heparin, by assessing agreement with established comparators. 185 patients were enrolled and assessed at multiple timepoints (pre, intra and post-procedure). There was a total of 543 samples analysed with results compared between the HN cartridge assays and their corresponding assays on the previous cartridge (CK:CK, CKH:CKH, CRTH:CKH) or plasma fibrinogen level for CFFH-MA.

Results

- HN parameters and their comparators on the Global Haemostasis cartridge, were equal to or close to 1.0 (range: 1.00-1.14).
- Agreement was confirmed by Pearson correlation coefficients, ranging from 0.79-0.93.
- Functional Fibrinogen had acceptable agreement with plasma fibrinogen with a Spearman correlation coefficient of 0.68 (95% CI: 0.626-0.730)



Note: Tables recreated with approximate values for visual reference. See original publication for precise data.

Conclusion

This study clinically validates the new assays (RapidTEG heparinase and Function Fibrinogen heparinase) on the cartridge, demonstrating that the HN cartridge assays are substantially equivalent to their clinically established comparator assays. This was assessed by both Deming regression and bias estimation within pre-specified acceptable limits. Analysis supports the use in clinical scenarios where heparin levels are typically high, evidenced by consistency with previous studies, demonstrating close agreement of RTH-MA with CKH-MA, and moderate correlation between CFF-MA and plasma fibrinogen.

"The results support that the Heparin Neutralization cartridge can provide thromboelastography measurements even in the presence of a significant heparin effect, potentially expanding the utility of point-of-care thromboelastography..."

* Adelmann D, Hartmann J, Moore HB., *TEG® 6s heparin neutralization cartridge for hemostatic assessment of patients undergoing cardiovascular surgery.* Anesthesiology. 2025; https://doi.org/10.1097/ALN.0000000000005759

For a list of worldwide office locations and contact information, visit www.haemonetics.com/officelocations

© 2026 Haemonetics Corporation. Haemonetics and TEG are a trademark or registered trademark of Haemonetics Corporation in the USA, other countries, or both. 01.2026 Switzerland. COL-COPY-002646-IE(AA)

HAEMONETICS®